SCM
XENE icon

Squadron Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Squadron Capital Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-105,551
Closed -$4.73M – 49
2025
Q4 		$4.73M Buy
+105,551
New +$4.43M 2% 15

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Squadron Capital Management's XENE Position: Q1 2026 in Review

Squadron Capital Management sold out of Xenon Pharmaceuticals (XENE) in Q1 2026, closing a stake of 105,551 shares — an estimated $4.73M sold.

Squadron Capital Management first reported a position in XENE in Q4 2025 and held it in 1 quarter. The position peaked at $4.73M in Q4 2025. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Squadron Capital Management reported no remaining Xenon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Squadron Capital Management sold 105,551 Xenon Pharmaceuticals shares in Q1 2026, an estimated $4.73M.
  • Squadron Capital Management first reported a position in Xenon Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Squadron Capital Management's Xenon Pharmaceuticals position peaked at $4.73M in Q4 2025.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Squadron Capital Management's 13F filing for Q1 2026, filed 15 May 2026.